ARCT Ends $4.3B CSL Vaccine Deal, Shifts to Cystic Fibrosis

Arcturus Therapeutics (ARCT) terminated its $4.3 billion self-amplifying mRNA vaccine collaboration with CSL Seqirus on August 6, disclosed alongside second-quarter earnings. The settlement returns global rights to KOSTAIVE, the world’s first approved sa-mRNA COVID-19 vaccine, to Arcturus, along with seasonal flu, pandemic flu, RSV, and EBV vaccine programs. CSL will pay $12 million in cash and release Arcturus from roughly $16 million in R&D credit liabilities, an effective $28 million settlement on a deal that was signed in November 2022 with $200 million upfront and up to $4.3 billion in milestones.

Arcturus stock closed at $7.41 on August 7, giving the company a market capitalization of roughly $160 million. The stock has traded in a narrow range since the announcement, reflecting the market’s view that the original deal’s milestone structure had been largely written off as COVID vaccine demand collapsed.

Revenue for the second quarter fell to $3.0 million from $28.3 million a year earlier, driven by the reduction in collaboration revenue as the CSL partnership unwound. Cash and cash equivalents stood at $191.5 million as of June 30. Management guided to a cash runway beyond year-end 2028, more than two and a half years at current spend.

The investment thesis has shifted entirely from vaccines to rare disease. ARCT-032, an inhaled mRNA therapy for cystic fibrosis, is now the lead asset. The drug uses the same LUNAR lipid nanoparticle delivery platform that KOSTAIVE validated. An open-label Phase 2 study evaluating 10 mg daily dosing over 12 weeks is enrolling patients with Class I CF mutations, the population that produces no CFTR protein and cannot benefit from Vertex’s modulator drugs. Enrollment is active in the US, Israel, and Turkey, and the decision to advance to Phase 3 is expected in the fourth quarter of 2026.

Arcturus secured a manufacturing and clinical services deal with Thermo Fisher in July 2026 that provides up to $40 million in clinical manufacturing and $40 million in CRO support for a potential Phase 3 program, with exclusive commercial manufacturing rights if the drug reaches market.

KOSTAIVE remains an approved product in Japan (since November 2023), the European Union (February 2025), and the United Kingdom (January 2026). Meiji Seika Pharma retains commercialization rights in Japan for the 2026-2027 season under a pre-existing arrangement that survives the CSL termination. Arcturus now faces the choice of finding a new commercialization partner or licensing the vaccine portfolio to a third party. The platform technology also underpins an H5N1 pandemic flu program that received FDA Fast Track designation in April 2025.

The near-term risk is ARCT-032 Phase 2 failure. Inhaled mRNA for CF has no efficacy data in humans. The Phase 2 is open-label with no placebo control. A negative go/no-go decision in Q4 2026 eliminates the rare disease thesis and leaves Arcturus with $191.5 million in cash and a vaccine platform without a partner. A green light means a Phase 3 program the company cannot fully fund without dilution or a new partner.

The broader mRNA platform story has been covered in this mRNA platform analysis. The Q2 2026 results confirmed the CSL termination terms and provided updated pipeline timelines. The lesson from the Arcturus-CSL unwinding is that platform validation through regulatory approval does not guarantee commercial viability when the underlying market has shrunk. For investors, the near-term catalyst is the ARCT-032 Phase 2 data and Phase 3 go/no-go decision in Q4 2026.

What It Means for the Trade

Start with the number that frames everything: a $160 million market cap against $191.5 million in cash. The stock is trading below net cash, which means the market values the entire operating company — platform, pipeline, KOSTAIVE rights, manufacturing deals — at less than zero. That is either a value trap or a deep-value setup, and the difference is entirely ARCT-032’s Q4 go/no-go. Below-cash trading in biotech usually reflects one of two beliefs: the cash will be burned on a program with no exit, or the market simply doesn’t price the assets because no catalyst forces it to. Here the catalyst is dated and public: the Phase 2 readout and Phase 3 decision in Q4 2026.

The trade structure is clean if you respect the binary. A green light means a funded-into-2028 rare-disease story with a Thermo Fisher manufacturing deal (up to $80 million combined in clinical manufacturing and CRO support, plus exclusive commercial manufacturing rights) that reads like a pre-built Phase 3 supply chain — and a Phase 3 program the company admits it cannot fully fund alone, so expect dilution or partnering into any positive readout. A no-go means the rare-disease thesis is gone, and the stock becomes a vaccine platform looking for a partner with $191.5 million behind it and few visible buyers. The settlement itself — $12 million cash plus release of roughly $16 million in R&D credit liabilities, on a deal originally carrying $200 million upfront and up to $4.3 billion in milestones — is the market’s quiet confirmation that nobody expected those milestones. The write-off happened in the stock long before the press release.

Pipeline and Platform Context

The pivot from vaccines to ARCT-032 is a story about delivery, not disease. Cystic fibrosis Class I mutations produce no functional CFTR protein, so the modulator therapies that dominate the CF market (Vertex’s franchise) have nothing to correct — roughly 10% of the CF population by class prevalence — and the unmet need is genuinely unsolved. Inhaled mRNA encoding functional CFTR, delivered by the LUNAR lipid nanoparticle platform that KOSTAIVE validated at scale, is conceptually the right tool: transient protein expression in airway epithelium without genome integration. The open-label Phase 2 (10 mg daily over 12 weeks, enrolling in the US, Israel, and Turkey) will produce the first real human efficacy signal for inhaled mRNA in CF — no placebo comparison disclosed, and open-label lung-function improvements in CF trials have a well-known optimism bias. The go/no-go framework management set for Q4 means the data either clears their own bar or it doesn’t.

KOSTAIVE itself remains an approved product in Japan, the EU, and the UK, but approvals don’t pay for Phase 3s without a commercialization engine — CSL was the engine, and Meiji covers only Japan’s 2026-2027 season. Finding a new vaccine partner or out-licensing the portfolio (seasonal flu, pandemic flu, RSV, EBV, plus the Fast-Track H5N1 program) is a live to-do that would add non-dilutive cash, but the market has heard “we’ll find a partner” from post-COVID vaccine platforms for years now.

Risks and What Could Go Wrong

1. ARCT-032 Phase 2 reads out marginal: open-label single-arm data that doesn’t clear the internal go bar kills the thesis without even a formal failure, and the stock has no second act priced.
2. The go decision forces funding on unfavorable terms — a Phase 3 in CF with $191.5 million and no partner means dilution at whatever price the market is giving that quarter.
3. LNP inhalation safety: repeat-dose inhaled lipid nanoparticles in chronically inflamed CF airways is a novel exposure with no clinical precedent; any safety finding is program-ending.
4. Vaccine partnering drags: if no KOSTAIVE successor deal materializes, the cash runway math (“beyond 2028”) starts doing all the valuation work, and burn-heavy quarters erode the below-cash cushion.

Position read: below-cash microcap with a dated binary is lottery-ticket territory — the sizing discipline is the whole trade. Q4 2026 is the tell; everything before it is noise.